Hua Medicine (Shanghai) Ltd. operates as a drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. The company also offers Dorzagliatin in combination with GLP1RA for T2D and obesity; in combination with insulin to treat Type 1 Diabetes; second generation glucokinase (GK) inhibitor for metabolic disease; mGLUR5 negative allosteric modulator (NAM) for PD-LID and drug addiction; and GK NAM for metabolic disease. The company was incorporated in 2011 and is based in Shanghai, China.
Metrics to compare | 2552 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship2552PeersSector | |
---|---|---|---|---|
P/E Ratio | −9.0x | −18.2x | −0.6x | |
PEG Ratio | 0.22 | 0.07 | 0.00 | |
Price/Book | −71.5x | 1.8x | 2.6x | |
Price / LTM Sales | 21.8x | 4.6x | 3.0x | |
Upside (Analyst Target) | 41.5% | 63.4% | 51.6% | |
Fair Value Upside | Unlock | −1.1% | 9.3% | Unlock |